| Eli Lilly & Co. | Metabolic & Cardiometabolic | $1.3t | $1347.00 | -0.2% | 2.5M | |
| Johnson & Johnson | Immunology & Autoimmune | $0.6t | $270.75 | +1.3% | 8.1M | |
| ABBVIE INC. | Immunology & Autoimmune | $0.5t | $285.95 | +0.9% | 5.3M | |
| Merck & Co., Inc. | Infectious Disease & Vaccines | $356.9b | $134.06 | +1.1% | 11.2M | |
| AstraZeneca PLC | Metabolic & Cardiometabolic | $285.2b | $173.77 | -0.6% | 1.7M | |
| Thermo Fisher Scientific, Inc. | Clinical-Stage Platforms | $258.7b | $678.26 | -2.8% | 1.9M | |
| Amgen Inc | Rare Disease TherapeuticsImmunology & Autoimmune | $249.4b | $438.02 | -0.6% | 2.7M | |
| Gilead Sciences Inc | Infectious Disease & Vaccines | $207.7b | $167.22 | -0.1% | 5.0M | |
| Pfizer Inc. | Infectious Disease & Vaccines | $171.0b | $27.43 | -0.4% | 26.6M | |
| Vertex Pharmaceuticals Inc | Rare Disease Therapeutics | $134.5b | $516.00 | -1.1% | 1.2M | |
| Bristol-Myers Squibb Co. | Immunology & Autoimmune | $126.1b | $59.00 | +1.1% | 9.4M | |
| Regeneron Pharmaceuticals Inc | Immunology & Autoimmune | $100.7b | $911.22 | -0.2% | 643.5K | |
| Moderna, Inc. Common Stock | Infectious Disease & Vaccines | $91.2b | $199.00 | -2.1% | 8.4M | |
| Agilent Technologies Inc. | Clinical-Stage Platforms | $49.5b | $172.17 | -3.0% | 1.4M | |
| Waters Corp | Clinical-Stage Platforms | $45.2b | $445.85 | -3.5% | 1.2M | |
| IQVIA Holdings Inc. | Clinical-Stage Platforms | $43.3b | $251.61 | -1.9% | 950.8K | |
| Biogen Inc. Common Stock | Neuroscience & CNS | $36.8b | $250.00 | +1.1% | 711.3K | |
| Royalty Pharma plc Class A Ordinary Shares | Clinical-Stage Platforms | $29.6b | $68.52 | +1.1% | 2.8M | |
| West Pharmaceutical Services, Inc. | Clinical-Stage Platforms | $28.4b | $390.44 | -1.6% | 449.5K | |
| Roivant Sciences Ltd. Common Shares | Immunology & Autoimmune | $26.0b | $38.65 | -0.8% | 3.1M | |
| United Therapeutics Corp | Rare Disease Therapeutics | $25.8b | $550.29 | -0.9% | 282.0K | |
| Incyte Genomics Inc | Rare Disease Therapeutics | $24.0b | $114.75 | -1.1% | 1.1M | |
| Insmed, Inc. | Rare Disease Therapeutics | $22.9b | $142.50 | -2.1% | 5.1M | |
| Alnylam Pharmaceuticals, Inc. | Rare Disease Therapeutics | $21.4b | $144.34 | -2.8% | 1.9M | |
| Medpace Holdings, Inc. Common Stock | Clinical-Stage Platforms | $18.6b | $619.84 | -3.8% | 201.4K | |
| Revvity, Inc. | Clinical-Stage Platforms | $18.2b | $149.47 | -4.2% | 1.2M | |
| Charles River Laboratories International, Inc. | Clinical-Stage Platforms | $16.8b | $324.55 | -3.8% | 865.5K | |
| Neurocrine Biosciences Inc | Neuroscience & CNS | $16.8b | $161.15 | -3.8% | 1.3M | |
| Ascendis Pharma A/S Ordinary Share | Clinical-Stage Platforms | $16.5b | $253.10 | -1.2% | 454.5K | |
| Icon Plc | Clinical-Stage Platforms | $15.3b | $186.88 | -1.8% | 552.3K | |
| Jazz Pharmaceuticals, Inc. | Neuroscience & CNS | $14.9b | $230.66 | -2.6% | 724.9K | |
| Halozyme Therapeutics, Inc. | Clinical-Stage Platforms | $14.6b | $94.82 | -1.8% | 1.1M | |
| BridgeBio Pharma, Inc. Common Stock | Rare Disease Therapeutics | $14.4b | $76.13 | -2.7% | 1.2M | |
| Summit Therapeutics Inc. Common Stock | Infectious Disease & Vaccines | $12.6b | $10.09 | -5.8% | 6.0M | |
| Bio-Techne Corp. | Clinical-Stage Platforms | $11.4b | $72.85 | -0.0% | 3.4M | |
| Repligen Corp | Clinical-Stage Platforms | $11.3b | $163.75 | -3.9% | 606.9K | |
| Kymera Therapeutics, Inc. Common Stock | Clinical-Stage Platforms | $10.8b | $123.75 | -3.6% | 965.4K | |
| BioMarin Pharmaceuticals Inc | Rare Disease Therapeutics | $10.8b | $60.44 | -1.6% | 4.8M | |
| Avantor, Inc. | Clinical-Stage Platforms | $10.6b | $15.10 | -1.9% | 10.5M | |
| QIAGEN N.V. | Clinical-Stage Platforms | $10.4b | $49.31 | -0.7% | 2.5M | |
| Apogee Therapeutics, Inc. Common Stock | Immunology & Autoimmune | $10.2b | $135.09 | 0.0% | N/A | |
| Vaxcyte, Inc. Common Stock | Infectious Disease & Vaccines | $9.6b | $55.71 | -5.0% | 1.4M | |
| Twist Bioscience Corporation Common Stock | Clinical-Stage Platforms | $9.3b | $104.01 | -7.4% | 2.7M | |
| TG Therapeutics, Inc. | Neuroscience & CNSImmunology & Autoimmune | $9.3b | $63.73 | -2.4% | 1.7M | |
| Spyre Therapeutics, Inc. Common Stock | Immunology & Autoimmune | $9.3b | $93.55 | -4.2% | 625.9K | |
| Madrigal Pharmaceuticals, Inc. Common Stock | Metabolic & Cardiometabolic | $9.2b | $393.45 | -4.5% | 287.8K | |
| Protagonist Therapeutics, Inc | Metabolic & CardiometabolicImmunology & Autoimmune | $9.1b | $121.46 | -2.0% | 515.1K | |
| Krystal Biotech, Inc. Common Stock | Rare Disease Therapeutics | $9.0b | $308.68 | -2.3% | 225.7K | |
| Corcept Therapeutics Inc. | Rare Disease Therapeutics | $8.9b | $63.01 | -2.1% | 826.7K | |
| Crinetics Pharmaceuticals, Inc. | Rare Disease Therapeutics | $8.8b | $84.97 | 0.0% | N/A |